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Abstract
This study aimed at determining the recommended dose of the mammalian tar-
get of rapamycin inhibitor everolimus in combination with mitomycin C
(MMC) in patients with previously treated metastatic esophagogastric cancer. In
this phase I trial, patients received escalated doses of oral everolimus (5, 7.5, and
10 mg/day) in combination with intravenous MMC 5 mg/m
2 every 3 weeks.
Endpoints were the dose-limiting toxicity (DLT), safety, and response rates.
Tumor tissues were tested for HER2-status and mutations in the PTEN, PIK3CA,
AKT1, CTNNB1, and E-cadherin type 1 genes. Sixteen patients (12 male, four
female) with gastric/gastroesophageal junction cancer were included. All patients
were previously treated with a platinum-based chemotherapy. Treatment cohorts
were: 5 mg/day, three patients; 7.5 mg/day, three patients; and 10 mg/day,
10 patients. No DLTs occurred during dose escalation. Most frequent grade 3
toxicities were leukopenia (18.8%) and neutropenia (18.8%). All other grade 3
toxicities were below 10%. No grade 4 toxicities occurred. Three (18.8%)
patients experienced partial responses and four patients had stable disease (SD).
Antitumor activity according to Response Evaluation Criteria In Solid Tumors
(RECIST)-criteria was highest in the 10 mg/day cohort. No associations between
HER2-status or detected mutations and response were observed. The recom-
mended dose of everolimus combined with MMC is 10 mg/day. Encouraging
signs of antitumor activity were seen (http://www.ClinicalTrials.gov; Clinical trial
registration number: NCT01042782).
Introduction
Gastric cancer is often diagnosed in locally advanced or
metastatic stages and, therefore, of poor prognosis. Sys-
temic chemotherapy is widely accepted as palliative
treatment, leading to objective responses, improvement
of the quality of life, and prolonged survival [1–3].
Based on response results of several combination che-
motherapy regimens, advanced gastric cancer is consid-
ered to be a chemotherapy-sensitive disease. However,
results of survival have been unsatisfactory so far, with
a median survival time ranging between 6 and
8 months [4].
The therapeutic standard in the ﬁrst-line setting for
gastric cancer or cancer of the esophagogastric junction
(EGJ) is either cisplatin/5-FU, oxaliplatin/5-FU, with or
without epirubicin or docetaxel. Capecitabine could
replace 5-FU in most of the schedules. At the time this
study was designed, there was no chemotherapy regimen
considered to be the standard of care in the second line
for patients with advanced gastric cancer. Most recently,
taxanes and irinotecan have been proved effective in the
second-line setting [5]. However, new protocols remain
warranted in this setting.
Everolimus is a derivative of rapamycin and has been
investigated as an anticancer agent based on its potential to
act directly on the tumor cells by inhibiting tumor cell pro-
liferation and tumor growth in situ. The target of
everolimus is mTOR (mammalian target of rapamycin), a
serine–threonine kinase which is a member of the larger
PI3K (phosphatidylinositol 3-kinase) family and present in
all cells. Several preclinical studies have indicated dys-
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Mutations in upstream regulators of mTOR signaling path-
way epithelial growth factor receptor [6] (EGFR), PI3K [6],
and PTEN [7] have been observed in patient-derived
gastric tumor samples. Patient-derived gastric cancer sam-
ples have been shown to express phosphorylated mTOR
indicative of mTOR activation [8–11], which has been pos-
itively correlated with tumor progression and poor survival
in patients with gastric cancer [9, 11, 12]. mTOR inhibitors
alone or in combination with other agents signiﬁcantly
delayed tumor progression in xenograft models of gastric
cancer [8, 13].
Mitomycin C (MMC) represents a well-tolerable,
active, and low-cost chemotherapy. As a single agent,
MMC at 10–15 mg every 6–8 weeks is considered one of
the most active single agents in gastric cancer, as it has
achieved consistent response rates in the 20–30% range
[14]. It is approved for gastric cancer in all settings and is
accepted as an option for patients with gastric cancer
who failed ﬁrst-line treatment. Previous studies have
already established the efﬁcacy of MMC in the treatment
of gastric cancer and have shown that it is well tolerable
[15]. The toxicity proﬁle of MMC is mainly hemato-
logical. Dose-limiting toxicities (DLTs) are leukopenia
and thrombocytopenia. When this study was designed,
the efﬁcacy of new drugs in the second-line treatment of
gastric cancer such as irinotecan and paclitaxel was
unknown. Furthermore, everolimus monotherapy was
under evaluation in phase I trials.
In this study, we conducted a phase I trial of everoli-
mus in combination with MMC to determine the recom-
mended dose and the DLT of everolimus plus MMC in
advanced gastric cancer or cancer of the EGJ for a future
randomized trial.
Materials and Methods
Patient eligibility
Main eligibility criteria were patients 18 years of age with
histologically conﬁrmed diagnosis of metastatic gastric can-
cer or adenocarcinoma of the EGJ; CT or MRI scan had to
demonstrate measurable disease by Response Evaluation
Criteria In Solid Tumors (RECIST)-criteria; and at least
one prior chemotherapy in the palliative setting or progres-
sive disease under adjuvant or neoadjuvant therapy within
6 months of treatment start date. Further criteria were
Eastern Cooperative Oncology Group performance status
(ECOG) 1, Life expectancy >4 months, sufﬁcient renal,
hepatic and bone marrow function.
Participants gave written informed consent before they
entered the study, which was approved by the responsible
ethics committee.
Treatment
Patients received MMC 5 mg/m
2 intravenously as a bolus
injection every 3 weeks in combination with oral doses of
everolimus at 5 mg/7.5 mg/10 mg per day starting 3 days
prior to MMC. Cycles were repeated every 3 weeks. A 3-
patient cohort, dose-escalating study design was used. The
initial dose of everolimus was 5 mg and was increased by
2.5 mg in the next cohort, provided that all patients in
the previous cohort ﬁnished their ﬁrst cycle of treatment
without experiencing a DLT. In case a patient experienced
a DLT, three additional patients were enrolled at the same
dose level. If only one of the six patients treated at the
same dose level experienced a DLT, the trial continued at
the next higher dose level. If two or more patients out of
the six exhibited DLT, the maximum tolerated dose
(MTD) was supposed to be surpassed and dose escalation
stops at that level. Intrapatient dose escalation was not
permitted. It was predeﬁned that dose escalation of ever-
olimus will be stopped at 10 mg/day in case a MTD is
not achieved. Patients were treated with everolimus until
progression of tumor, the occurrence of unacceptable tox-
icity, or until the investigator or patient decided that con-
tinuation is not in the best interest of the patient.
Toxicity evaluation and dose adjustments
Toxicity was assessed using the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-
CTCAE), version 3.0. DLT was deﬁned as a hypersensitiv-
ity reaction grade 2, any grade 3 nonhematologic
toxicity (except alopecia and mucositis lasting less than
7 days), grade 4 thrombocytopenia and grade 4 neutro-
penia persisting >5 days. Adverse events were considered
dose limiting when they were at least possibly related to
the study treatment, that is, the combination of everoli-
mus and MMC, and they were considered for the deﬁni-
tion of the MTD when they occurred during the ﬁrst
cycle of treatment (ﬁrst cycle DLT). Abnormal laboratory
values were considered dose limiting when they, in addi-
tion, were considered as clinically signiﬁcant. For patients
who were unable to tolerate the protocol-speciﬁed everol-
imus dosing schedule, the dose of everolimus was
adjusted in 2.5 mg reduction steps.
Response and survival evaluation
Objective responses were deﬁned based on RECIST-
criteria (version 1.0). Progression-free survival (PFS) was
deﬁned as the time from ﬁrst study drug administration
to objective tumor progression or death from any cause.
Overall survival (OS) was deﬁned as the time from ﬁrst
study drug administration to death from any cause. The
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during the treatment and 3 months after end of study.
Survival evaluation was also 3 months after end of study.
Biomarker studies
Patient tissue was analyzed for hot spot mutations or poly-
morphisms in phosphatase and tensin homolog (PTEN),
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha (PIK3CA), v-akt murine thymoma viral
oncogene homolog 1 (AKT1), cadherin-associated protein
beta 1 (CTNNB1), and E-cadherin type 1 (CDH1) with
conventional DNA sequencing (ABI 3500DX Genetic Ana-
lyzer, Applied Biosystems, Foster City, CA) and optimized
standard PCR conditions. DNA was extracted from paraf-
ﬁn-embedded tumor tissue using QIAamp DNA Tissue Kit
(Qiagen, Hilden, Germany).
The primer sequences were PTEN (exon 2) F: 5′-TGAC-
CACCTTTTATTACTCC-3′,R :5 ′-AGTATCTTTTTCT
GTGGC-3′, PTEN (exon 3) F: 5′-CTACTC TAAACCCATA-
GAAGG-3′,R :5 ′-CCTCACTCTAACAAGCAG-3′, PTEN
(exon 5) F: 5′-GCAACATTTCTAAA-GTTACCTAC-3′,R :5 ′-
CAATAAATTCTCAGATCCAGG-3′, PTEN (exon 6) F: 5′-
CAT-AGCAATTTAGTGAAATAACT-3′,R :5 ′-G A T A T G G T
TAAGAAAACTGTTC-3′, PTEN (exon 7) F: 5′-T G A -
CAGTTTGACAGTTAAAGG-3′, PTEN (exon 8) F: 5′-
GCAACATTT-CTAAAGTTACCTAC-3′,R :5 ′-CATACATAC
AAGTCAACAACC-3′, PTEN (exon 9) F: 5′-GAGTCA
TATTTGTGGGTT-3′,R :5 ′-GACACAATGTCCTA TTGC-
CAT-3′, Akt1 (exon 4) F: 5′-CACACCCAGTT CCTGCCT-3′,
CTNNB1 (exon 3) F: 5′- GCTGATTTGATGGA-GTTGGA-3′,
R: 5′-GCTACTTGTTCTTGAGTGAA-3′, CDH1 (exon 6) F:
5′-CTC-ACTTGGTTCTTTCAG-3′,R :5 ′-AACCTTTGGG
CTTGGACA-3′, CDH1 (exon 7) F: 5′-AGCTTGTCTAAAC
CTTCATC-3′,R :5 ′-GCTTAGACCA TCACTGTATT-3′,
PIK3CA (exons 10, formerly exons 9) F: 5′-G A T -
TGGTTCTTTCCTGTCTCTG-3′,R :5 ′- CCACAA-ATA-
TCAATTTACAACCATTG-3′,a n dPIK3CA (exon 21,
formerly exon 20) F: 5′-CATTTGCTCCAAACTGACCA-3′,R :
5′-TGTGGAATCCAGAGTGAGCTT-3′.
To determine the HER2-status, immunohistochemistry
(IHC; 4B5 antibody) and silver in situ hybridization
(SISH) were used. The IHC and SISH results were inter-
preted using the scoring scheme proposed for gastric can-
cer by Hofmann et al. [16] (ToGA score) and R€ uschoff
et al. [17].
Results
Patients
Sixteen patients were enrolled in three treatment cohorts
at three dose levels: 5 mg/day, three patients; 7.5 mg/day,
three patients; and 10 mg/day, 10 patients (the 10 mg
cohort was extended to 10 patients as an MTD was not
achieved and no further escalation was planned). Patients’
characteristics are summarized in Table 1. Twelve patients
were male and the median age was 63 (range, 36–88)
years. All patients were pretreated with a median of 2
(range, 1–6) prior chemotherapy lines. All patients had
received a platinum-based chemotherapy and almost all
patients (14/16) had also received docetaxel.
Safety and DLT
Median treatment duration was 52 days (range, 13–
321 days). A total of 51 cycles of chemotherapy/everoli-
mus were administered with an overall median of 2 cycles
(range, 1–12). Median numbers of cycles administered
per cohort were 2 (range, 1–4) in the 5 mg cohort, 2
(range, 2–2) in the 7.5 mg cohort, and 3 (range, 1–12) in
the 10 mg cohort. Adverse events according to cohort
Table 1. Patients characteristics.
Patients characteristics
No. of patients (%)
n = 16
Sex
Male 12 (75.0)
Female 4 (25.0)
Age
Median age, years (range) 63 (36–88)
ECOG performance status
0 5 (31.3)
1 11 (68.8)
Primary tumor location
Gastroesophageal junction 6 (37.5)
Mid to distal stomach 10 (62.5)
No. of organs involved (primary tumor excluded)
1 3 (6.3)
2 5 (31.3)
3 3 (6.3)
4 5 (31.3)
Organs involved (primary tumor excluded)
Liver 12 (75.5)
Lymph nodes 10 (62.5)
Peritoneum 7 (43.8)
Lung 4 (25.0)
Other
1 9 (56.3)
Lauren classiﬁcation
Diffuse/mixed 6 (37.5)
Intestinal 10 (62.5)
No. of previous lines of chemotherapy
1 5 (31.3)
2 6 (37.5)
3 5 (31.3)
ECOG, Eastern Cooperative Oncology Group.
1Other: adrenal gland, spleen, pancreas, bones, duodenum, rectum,
adrenal, retroperitoneal lymphoma.
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most commonly observed all grade toxicities, possibly
related to the treatment were leukopenia in 10 patients
(62.5%), nausea in 10 patients (62.5%), neutropenia in
nine patients (56.3%), mucositis/stomatitis in nine
patients (56.3%), alopecia in eight patients (50.0%), and
thrombocytopenia in eight patients (50.0%). The most
commonly observed grade 3 toxicities were leukopenia in
three patients (18.8%) and neutropenia in three patients
(18.8%). The most commonly observed grade 3 toxicities
were leukopenia (18.8%) and neutropenia (18.8%). Leu-
kopenia and neutropenia were the only grade 3 events in
the 5 mg cohort, observed in one patient each. No grade
3 toxicities were documented in the 7.5 mg cohort. In the
10 mg cohort, several grade 3 events were observed,
which comprised leukopenia and neutropenia in two
patients each, and mucositis, lymphopenia, anemia, and
diarrhea with infection in one patient each.
For dose escalation, ﬁrst cycle DLTs were considered.
No DLTs during the ﬁrst cycle were observed in any of
the cohorts during the dose escalation phase. No DLTs
were observed in the 5 and 7.5 mg in any cycle. Also no
DLTs occurred in the ﬁrst three patients of the 10 mg
cohort. As a further dose escalation was not planned and
to gain more information on safety and tolerability, the
10 mg cohort was extended to a total of 10 patients.
In the extended phase, one DLT was observed in patient
#14. The patient suffered grade 3 diarrhea accompanied
by bacterial infection and dehydration during the second
cycle of his treatment. A causal relation to the study treat-
ment could not be excluded.
Activity
The characteristics of disease together with important cli-
nico-pathological criteria are given in Table 3. On ﬁrst
response evaluation, there were three patients (#2, #9, and
#14) with documented partial response, one patient (#2)
in the 5 mg cohort and two patients (#9 and #14) in the
10 mg cohort. Patient #9 in the 10 mg cohort had a
Table 2. Side effects with possible relationship to everolimus/mitomycin C.
Adverse event
5.0 mg (n = 3)
n
7.5 mg (n = 3)
n
10.0 mg (n = 10)
n
Total pts for all cohorts
(n = 16)
n
G1/G2 G3 Total G1/G2 G3 Total G1/G2 G3 Total G1/G2 G3 Total
Leukopenia 1 1 2 1 – 15 2 77 3 1 0
Nausea 1 – 13 – 36 – 61 0– 10
Oral mucositis/stomatitis 1 – 13 – 34 1 58 1 9
Neutropenia 1 1 2 1 – 14 2 66 3 9
Alopecia 1 – 1 –– – 7 – 78 – 8
Thrombocytopenia 1 – 1 –– – 7 – 78 – 8
Diarrhea 1 – 11 – 12 1 34 1 5
Lymphopenia –– – –– – 41 5 41 5
Anemia 3 – 31 – 1 – 11 4 15
Fatigue 1 – 1 –– – 4 – 45 – 5
Dry skin, rash or desquamation –– – –– – 4 – 44 – 4
Hyperglycemia –– – –– – 3 – 33 – 3
Vomiting –– – 1 – 12 – 23 – 3
Peripheral neuropathy 1 – 1 –– – 2 – 23 – 3
Infection –– – –– – 11 2 11 2
Fever 1 – 11 – 1 –– – 2 – 2
Hypoalbuminemia 1 – 11 – 1 –– – 2 – 2
Hyperbilirubinemia –– – –– – 11 2 1– 2
Pain –– – –– – 1 – 11 – 1
Pruritus/itching –– – –– – 1 – 11 – 1
Edema: limb –– – 1 – 1 –– – 1 – 1
Constipation –– – 1 – 1 –– – 1 – 1
Hypocalcemia 1 – 1 –– – –– – 1 – 1
Dizziness 1 – 1 –– – – – – – 1 – 1
GGT elevation 1 – 1 –– – –– – 1 – 1
Insomnia 1 – 1 –– – –– – 1 – 1
Hypertriglyceridemia 1 – 1 –– – –– – 1 – 1
GGT, gamma-glutamyl transpeptidase.
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than 11 months (Fig. 1). Response rates favored the
10 mg cohort, in which four patients had SD and one
patient had a long lasting objective response. Additionally
the rates of progressive disease as best response were 2/3
(66.6%), 3/3 (100%), and 3/10 (30%) in the 5, 7.5, and
10 mg cohorts, respectively. Median OS for patients in
the 5, 7.5, and 10 mg cohorts were 2.6, 3.5, and
7.2 months, respectively, and median PFS were 1.5, 1.6,
and 2.6 months, respectively.
Correlative studies
Three of 15 (20%) assessed patients showed HER2 over-
expression (Table 3). In the mutational analysis, a total of
three genetic variants were identiﬁed in the region of
PTEN and one in the AKT1 gene (Table 3). Two of the
variants, single nucleotide polymorphism (SNP)
rs1903858 in PTEN and SNP rs3730358 in AKT1, were
intronic SNPs and two were missense substitutions
(p.H397Y and p.G36E, both in PTEN). All four detected
variants had already been previously described (http://
www.ncbi.nlm.nih.gov/SNP/; http://www.sanger.ac.uk/
genetics/CGP/cosmic/). PIK3CA, AKT1, CTNNB1, or
CDH1 hotspot mutations were not found. None of the
genetic variants evaluated was observed in patient number
nine who had a favorable clinical development.
Discussion
We performed a dose escalation Phase I study of everol-
imus in combination with the cytotoxic agent MMC in
patients with advanced gastric cancer or cancer of the
EGJ who were resistant to prior standard chemotherapy.
We demonstrated that oral everolimus at the standard
dose of 10 mg/day can be safely combined with a cyto-
toxic drug such as MMC. The adverse events observed
were generally mild. With the exception of hematological
toxicity, which was most likely related to MMC (leuko-
penia 18.8%, neutropenia 18.8%, and anemia 6.3% for all
doses), individual grade 3 adverse events possibly related
to the treatment did not exceed the 10% range in any
cohort. Unexpected toxicities and grade 4 toxicities did
not occur and the overall side effects were consistent with
previous reports, in which frequently occurring adverse
events related to everolimus were stomatitis/oral mucosi-
tis, fatigue, anorexia, hyperglycemia, hyperlipidemia, ele-
vated liver enzymes, diarrhea, and hypophosphatemia
[18–21]. Most grade 3 toxicities in our trial were seen in
the 10 mg cohort. This may be related to the higher dose,
but also to longer study drug exposure in this cohort,
where individual patients were treated up to 11 months
and were more likely to experience toxicities. One impor-
tant ﬁnding in our trial is that everolimus could be com-
bined with the cytotoxic agent MMC at the standard
10 mg per day dose, which is the recommended dose for
everolimus in the monotherapy setting. This is in line
with a recent study, which evaluated everolimus in com-
bination with paclitaxel and trastuzumab for patients with
breast cancer and HER2 overexpression. In this phase Ib
dose escalation study, 30 patients were treated with ever-
olimus at different doses in combination with paclitaxel
and trastuzumab. Grade 3 to 4 neutropenia was the most
common toxicity (52%) and everolimus at 10 mg/day
was recommended for additional development [22]. Since
we chose the ﬁrst cycle DLT (3 weeks) as the primary
endpoint, the long-term tolerability should be reevaluated
carefully in future phase II trials, if MMC is combined
Figure 1. Objective response under everolimus/MMC treatment in patient #9.
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MMC is known to cause prolonged myelosuppression.
Some signs of antitumor activity were seen. There were
three patients with objective responses, one of whom had
a dramatic and durable response, lasting 11 months. The
antitumor activity according to RECIST-criteria seemed
to be dose dependent, as all disease stabilizations and two
of three partial responses (of which one was durable)
occurred in the 10 mg cohort. Treatment duration and
survival time were also longer in the 10 mg cohort than
they were in the lower dose cohorts. This makes it more
likely that everolimus contributed to the activity observed
in some patients and is in line with encouraging signs of
antitumor activity that have been observed in early trials
with everolimus as single agent. In a phase I study of ev-
erolimus in nine Japanese patients with advanced solid
tumors, everolimus 10 mg/day resulted in a partial
response with a duration of >4 months in a heavily pre-
treated patient with gastric cancer and liver metastases [6].
In a recent phase II trial conducted in Japan, everolimus
10 mg/day was administered to 53 patients with previously
treated metastatic gastric cancer [19]. Although no com-
plete or partial responses were documented, 45% of
patients had a decrease in tumor size from baseline by
independent radiologic review. In another Korean phase II
trial of 54 patients with chemotherapy-refractory advanced
gastric cancer treated with everolimus 10 mg/day, two
(4%) patients achieved conﬁrmed partial responses [6].
The GRANITE-1 (gastric antitumor trial with everoli-
mus-1) phase III trial compared everolimus/supportive
care with placebo/best supportive care in previously
treated patients with advanced gastric cancer. In this
trial, everolimus has been found to be active, signiﬁ-
cantly improving PFS (hazard ratio, 0.66; 95% CI,
0.56–0.78; P < 0.001), but OS was not signiﬁcantly pro-
longed (hazard ratio, 0.90; 95% CI, 0.75–1.08;
P = 0.1244) [23].
Taken together, the data show that everolimus has
some activity in gastric cancer but objective responses
have been rare. This raises the questions of how many
gastric cancer patients really harbor inappropriate mTOR
activation and of whether the administration of everoli-
mus to unselected patient populations is meaningful.
Patient selection based on molecular events known to be
associated with mTOR activation such as the overexpres-
sion of PI3K/Akt and the growth factor receptors human
epidermal growth factor receptor 2 (HER2) and insulin-
like growth factor receptor (IGFR) as well as mutations in
PI3K and mutations/ampliﬁcations of Akt or downregula-
tion of PTEN may represent an appropriate way to iden-
tify populations that are more likely to show signiﬁcant
beneﬁt from mTOR inhibitors. Unfortunately, little was
known about the molecular proﬁles of patients who
responded to everolimus in initial trials. This has led us
to incorporate a biomarker analysis in our study, which
found genetic alterations related to PTEN in 12.5% (2/16)
of patients and related to AKT1 in one patient. Altera-
tions of PTEN by inactivating mutations and/or chromo-
somal deletions have been described in many different
tumor types including gastric cancer [24]. In our study,
we found one mutation in Exon 2 at Codon 36 (p.G36E),
which is published as a hot spot region and might have a
crucial role in the carcinogenesis or progression of gastric
cancer [7]. The other alterations including SNP rs1903858
(PTEN) and SNP rs3730358 (AKT1) were intronic vari-
ants that did not seem to have any functional conse-
quences, as they did not affect splice junctions. In
addition, we detected an overexpression of HER2 in 20%
(3/15) of patients. The responders did not harbor any
remarkable genetic alterations, but the number of patients
in this phase I study and the number of factors evaluated
and found were too limited to enable the discovery of rel-
evant biomarkers in our study. It is very important that
future studies identify potential markers of response to
everolimus and validate their role. An ongoing phase III
trial (n = 480) of our group (RADPAC trial) evaluates
paclitaxel monotherapy with or without everolimus in the
second- or third-line setting (NCT01248403). The study
administers everolimus to an unselected patient popula-
tion, but is accompanied by a comprehensive exploratory
biomarker research programs including next-generation
sequencing to identify genetic variants with potential link
to everolimus activity. We used MMC in the present
study, because it was the only approved drug for gastric
cancer in the second-line setting and could build an
acceptable comparator for a further phase III trial. How-
ever, the decision to combine everolimus with paclitaxel
and not with MMC in the RADPAC trial mentioned
above study was met after comprehensive discussions
mainly based on the encouraging results of everolimus/
paclitaxel combination achieved in larger patient popula-
tions with breast cancer.
In conclusion, the results of our phase I study suggest
that oral everolimus can be safely administered at
10 mg/day in combination with the cytotoxic drug
MMC at 5 mg/m
2 every 3 weeks in previously treated
patients with gastric cancer and adenocarcinoma of the
EGJ. Encouraging signs of antitumor activity were
observed, indicating that the combination of everolimus
and cytotoxic drugs for gastric cancer deserves further
evaluation.
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